Changes in the scope of business of well-known pharmaceutical companies, increased sales of pharmaceutical machinery, etc.

Pharmaceutical Network Enterprise News" recently, Ha Pharmaceutical Stakes issued a notice that on May 20, 2020, it received a letter from Ha Pharmaceutical Group Co., Ltdproposing to increase the interim proposal of the general meeting of shareholders, to increase the scope of business of the company's 8th 28th board of directors to consider and approve the "sales of pharmaceutical machinery" and "technical development in pharmaceutical machinery" and other contentdata show that Kazakhstan pharmaceutical shares focus on the pharmaceutical and health industry, mainly engaged in pharmaceutical research and development and manufacturing, wholesale and retail business, is a collection of pharmaceutical research and development, manufacturing, sales in one of the domestic large-scale high-tech pharmaceutical enterprisesThe company's main six business sectors, mainly covering antibiotics, traditional and modern Chinese medicine, biomedicine, pharmaceutical business, over-the-counter drugs and health care products, animal vaccinesnet profit on shares of Harpharma was 55.8121 million in 2019, down 83.88 percent from a year earlierThe report showed that this was mainly due to a decrease in annual cash sales and an increase in cash payments for purchases of goodsAffected by local policies such as the elimination of base drug supplements, the weakening of advertising effects, antibiotic restrictions, and adjustment of medical insurance catalogues, the company's leading varieties of laxidi flat, pediatric amino phenol jaundice, ibuprofen particles, iliamycin dispersion tablets, and the sales of predyl injections decreased significantly year-on-yearIt is worth noting that the net profit of Hapharmaceutical shares has fallen for three years in a rowIn 2017-2018, the net profit of the drug's shares fell by 48.36 percent and 14.95 percent, respectivelyin terms of product categories, more than half of its products fell in 2019Among them, anti-infective products, cold medicine products, cardiovascular products, digestive system products and anti-tumor products, respectively, achieved revenue of 1.04 billion yuan, 418 million yuan, 355 million yuan, 172 million yuan, 0.88 billion yuan, respectively, down 19.14%, 16.38%, 27.9%, 13.17% and 0.94%In 2019, the company's shares only increased revenue from nutritional supplements and other products, with revenue from nutritional supplements increasing 17.54 percent year-on-year to RMB1,273 million, while other products increased 10.3 percent year-on-year to RMB046 millionIn the first quarter of 2020, Hapharmaceutical's shares lost 187 million yuan in the first quarter, a decrease of 145 million yuan from a year earlierIt is understood that the main reason for the loss is due to the decrease in sales of high gross margin varieties compared to the same periodin response to the decline in performance in recent years, Kazakhstan pharmaceutical shares said that in the face of adverse factors, the company has accelerated the adjustment of various business sectors, set up a sound marketing organization structure, establish a cooperative relationship with large pharmaceutical commercial enterprises, the results of reform has been gradually shown in the second half of 2019, but the overall sales volume of products in the reporting period is still down from a year earlier, net profit decreased from a year earlier it is understood that since 2019, the shares of the drug continue to strengthen cooperation with retail pharmacies, pharmaceutical e-commerce and so on For example, in June-July 2019, HaPharmaceutical signed strategic cooperation agreements with China Pharmaceutical Holdings, Shuyu Civilian Pharmacy and 111 Group, respectively In September of the same year, Ha Pharmaceutical Group Marketing Co., Ltd and Jilin Big Pharmacy signed a chain of strategic cooperation agreements the current, the pharmaceutical machinery industry is supported by favorable policies, as well as the rapid development of the market at a time when the pharmaceutical machinery industry is widely optimistic The industry believes that, benefiting from the arrival of the industry inflection point, the future pharmaceutical machinery leader is expected to maintain steady growth, profitability or gradually improve Ha pharmaceutical shares this time into the pharmaceutical machinery field, or hope to seize the opportunity to increase the net profit growth point the author learned that, in addition to the drug, Kun Pharmaceutical Group also announced on May 8 to increase the scope of business, including pharmaceutical equipment manufacturing, installation and maintenance business, pharmaceutical engineering design and other content.